Cevc Gregor, Mazgareanu Stefan, Rother Matthias
IDEA AG, Frankfurter Ring 193a, D-80807 Munich, Germany.
Int J Pharm. 2008 Aug 6;360(1-2):29-39. doi: 10.1016/j.ijpharm.2008.01.051. Epub 2008 Feb 6.
We compared in vivo transport and biodistribution of ketoprofen applied on the skin in ultradeformable carriers (Diractin) or a conventional topical gel (Gabrilen) with oral drug (Oruvail); for reference we used in vitro study data. The drug from Gabrilen diffuses into body with low bioavailability (<10%) and limited regio-selectivity (AUC(deep muscle/plasma) approximately 45/0.8 (t=0-8h), reaching maximum concentration in subcutaneous tissues and plasma at similar time (t(max) approximately 3-4h). The apparent drug elimination half-life is then similar to oral ketoprofen (t1/2,a) approximately 2 h). In contrast, Diractin containing ultradeformable carriers (Transfersome vesicles) delivers the drug more efficiently (>50%) and more directly into peripheral muscles (AUC(deep muscle/plasma) approximately 447/0.7 (652/1.4) for t=0-8 (0-24)h; tmax approximately 1 h), arguably in non-diffusive fashion. Ketoprofen from Diractin moreover disappears from body periphery slower (t1/2,a) approximately 4-6 h), owing to sustained drug release from the carriers in target tissue. Final clearance always proceeds via plasma (tmax approximately 4 h). Epicutaneous application of ketoprofen in conventional gels or the carrier-based formulation thus leads to different local accumulations and clearances. Ketoprofen from Diractin achieves more desirable biodistribution and clearance, arguably due to spontaneous carrier-mediated drug transport across the skin, which ensures local and relatively long-lasting drug deposition into peripheral target tissues.
我们比较了酮洛芬在超可变形载体(Diractin)或传统局部用凝胶(Gabrilen)中经皮给药与口服给药(Oruvail)的体内转运和生物分布情况;作为参考,我们使用了体外研究数据。来自Gabrilen的药物以低生物利用度(<10%)扩散进入体内,区域选择性有限(AUC(深部肌肉/血浆)约为45/0.8(t = 0 - 8小时),在皮下组织和血浆中同时达到最大浓度(t(max)约为3 - 4小时)。然后,表观药物消除半衰期与口服酮洛芬相似(t1/2,a约为2小时)。相比之下,含有超可变形载体(传递体囊泡)的Diractin能更有效地(>50%)将药物更直接地递送至外周肌肉(t = 0 - 8(0 - 24)小时时,AUC(深部肌肉/血浆)约为447/0.7(652/1.4);tmax约为1小时),可以说是以非扩散方式。此外,来自Diractin的酮洛芬从身体外周消失得更慢(t1/2,a约为4 - 6小时),这是由于药物在靶组织中从载体持续释放。最终清除总是通过血浆进行(tmax约为4小时)。因此,在传统凝胶或基于载体的制剂中经皮应用酮洛芬会导致不同的局部蓄积和清除情况。来自Diractin的酮洛芬实现了更理想的生物分布和清除,这可以说是由于载体介导的药物自发经皮转运,从而确保了药物在局部和外周靶组织中的相对持久沉积。